EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oxford BioMedica's EBITDA for the
six
months ended in Dec. 2025 was £8.4 Mil. Oxford BioMedica's Revenue for the
six
months ended in Dec. 2025 was £95.5 Mil. Therefore, Oxford BioMedica's EBITDA margin for the quarter that ended in Dec. 2025 was 8.77%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Oxford BioMedica EBITDA Margin % Related Terms
Oxford BioMedica EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OXB vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Oxford BioMedica's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (LSE:OXB) has a EBITDA Margin % of 8.77% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #299 out of 945 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Oxford BioMedica's EBITDA Margin % too high?
Oxford BioMedica's current EBITDA Margin % is 8.77%. Based on the distribution chart, Oxford BioMedica ranks #299 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #299 out of 945 companies for EBITDA Margin %. This puts Oxford BioMedica in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current EBITDA Margin % is 8.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.14 — trading 14.6% above its estimated fair value. The current EBITDA Margin % is 8.77%. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current EBITDA Margin % is 8.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of £6.14 is trading 14.6% above its estimated GF Value™ of £5.36.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for LSE:OXB:
EBITDA Margin %: 8.77%
GF Value™: £5.36 vs. price of £6.14 (14.6% above fair value)
No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score
Get the complete analysis for LSE:OXB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OXB has been successfully added to your 
